Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs versus rituximab for ABO-incompatible liver transplantation
ChiCTR2000037732Phase 2Completed
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of umbilical cord-derived mesenchymal stromal cells and rituximab in hepatic failure (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Acute rejection and Safety of multi-dose UC-MSC administration. Started Aug 2016; status: completed.
02
Drugs
umbilical cord-derived mesenchymal stromal cellsrituximab
03
Conditions
hepatic failure
Beyond the preview
Go deeper on ChiCTR2000037732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037732.